New report 2026 AI SDR market benchmark: six platforms, eight workflow stages See the results →

Il rapporto

Notizie verificate su finanziamenti, sedi centrali e leadership delle aziende più innovative al mondo

82 report e oltre

Aggiornato quotidianamente con le ultime intelligence di mercato

KymaThera Raises $80M Series B for Selective PI3Kα Inhibitor

KymaThera raised an $80 million Series B led by Alta Partners to advance K-1728, an oral PI3Kα inhibitor for cancer and vascular malformations.

NeoGenomics Names Warren Stone Chief Executive Officer

NeoGenomics named President and COO Warren Stone CEO effective January 4, 2027, with Tony Zook becoming Executive Chair and the company emphasizing strategic continuity.

Teal Health Raises $22M Series A for At-Home HPV Cervical Cancer Screening

Teal Health raised a $22 million Series A led by .406 Ventures to expand partnerships and access to its at-home HPV cervical cancer screening.

Altis Labs Raises $25M Series A for AI Clinical-Trial Endpoints

Altis Labs raised a $25 million Series A co-led by OrbiMed and Qiming Venture Partners USA to expand AI endpoints for oncology clinical trials.

Solstice Oncology Raises $225M Series A for Neoadjuvant Immuno-Oncology

Solstice Oncology launched with a $225 million Series A led by RA Capital Management to advance porustobart, a neoadjuvant immuno-oncology therapy.

Cloverleaf Bio Raises $33M Seed Round for RNA Cancer Therapeutics

Cloverleaf Bio closed an oversubscribed $33 million seed round to advance engineered tRNA therapeutics for liver and colorectal cancers.

Craif Closes Approximately $33M Series D for Urine-Based Cancer Test

Craif closed an approximately $33 million Series D, made up of about $30.7 million in equity and about $3.3 million in debt and co-led by Granite-Integral and Tauns Co., Ltd., bringing total capital raised to roughly $88 million.